Despite the studies and progress made over the last 15 years on the use of stem cell therapy for cardiovascular disease, the efforts are still in their infancy. Even though the expectations have been high, the findings indicate that most of the clinical trials generally have been small and the results inconclusive. Due to many negative discoveries, there is certain pessimism that heart cell treatment is probably going to yield any significant outcomes throughout the following decade or something like that. Like other new innovations, early disappointments are not surprising and they might be trailed by noteworthy achievement. Nevertheless, there has been considerable attention to safety by the clinical investigators because the adverse events of stem cell therapy have been impressively rare. In outline, although regenerative science probably won't help the cardiovascular patient in the near term, it is destined to do as such throughout the next several decades
